Skip to content
Screener

Arcus Biosciences RCUS Q2 2026 earnings

Reported August 5, 2026 · After market close

Revenue$41.0MBeat by $19.0M
EPS-$0.72Beat by $0.17
Revenue estimate$22.0M
EPS estimate-$0.89
“The ARC-20 platform study and strategic clinical collaborations are enabling us to efficiently pursue an integrated approach across multiple lines of therapy, and we expect this year's upcoming ARC-20 data readouts in first-, second-and late-line settings to clarify casdatifan's potential to transform the treatment paradigm for kidney cancer.”
Terry Rosen

Next report

Oct 27, 2026 (in a month)
Revenue estimate$11.0M
EPS estimate-$0.89

Financials

Q2 2026

Income statement

See full
Revenue$41.0M-74.4%
Operating income-$96.0M-1,100%
Net income-$91.0M—
EPS (diluted)-$0.72—

Balance sheet

See full
Cash & equivalents$150.0M-39.5%
Total debt$114.0M+4.6%
Total equity$464.0M-15.5%
Total assets$924.0M-14.0%

Cash flow

See full
Operating cash flow-$119.0M+10.5%
CapEx-—
Free cash flow-$119.0M+10.5%

Valuation & ratios

Valuation

as of 09/17/26
See full
Market cap$3.14B+145%
Enterprise value$3.1B+172%
P/S26.8×+21.9×

Profitability

See full
Operating margin-415.4%-756pp
Net margin-393.2%-663pp
FCF margin-406%—

Returns & leverage

See full
Return on equity-90.8%+373pp
Debt / equity0.2×0.0×
Current ratio3.8×-0.7×

Segments

By product

See full
License$4.0M—
R&D services$4.0M+100%

By segment

See full
Reportable segment$41.0M-74.4%

FAQ

When did Arcus Biosciences report Q2 2026 earnings?
Arcus Biosciences (RCUS) reported Q2 2026 earnings on August 5, 2026 after market close.
What were Arcus Biosciences's Q2 2026 revenue and EPS?
Arcus Biosciences reported revenue of $41.0M and eps of $-0.72 for Q2 2026.
Did Arcus Biosciences beat estimates in Q2 2026?
Revenue beat the consensus estimate of $22.0M by $19.0M. EPS beat the consensus estimate of $-0.89 by $0.17.
How did Arcus Biosciences's Q2 2026 results compare year-over-year?
Compared to the same quarter a year prior, revenue declined 74.4% from $160.0M a year earlier and eps declined 858.5% from $-0.08.
Where can I find Arcus Biosciences's Q2 2026 SEC filings?
You can read the 8-K earnings release (0001724521-26-000042) and the 10-Q periodic report (0001724521-26-000044) directly on SEC EDGAR. The filing index links above go to sec.gov.